Patient Voices: Shaping the Future of Cancer Care

The Patient Voices panel at Cancer Progress 2025 was both a reckoning and a rallying cry. What began as personal storytelling quickly deepened into systemic critique—and ultimately, a blueprint for progress. It was a challenge to redefine whose experiences count in drug development and when their voices are allowed to matter.

Panelists shared stories of collapsed lungs, experimental immunotherapies, five-month inpatient stays, and caregiving that overtook every part of a previous life. But what emerged wasn’t just grief. It was strategic clarity.

These weren’t anecdotes. They were analysis. Advocates mapping blind spots, tracing failure patterns, and exposing how systems reward the compliant, delay the willing, and lose sight of the people caught at their center.

Patterns too painful to be coincidence

“Fail first” isn’t a safeguard—it’s a design flaw

The requirement that patients “fail first” on standard therapies before accessing clinical trials or innovative treatments drew sharp critique from every panelist. T.J. Sharpe, a twotime cancer survivor, spoke plainly: “No one should have to get worse to qualify for something better.”